20/20 Biolabs, Inc.

AI-generated fair value estimate for this company.

Method: EV/Revenue comparable-multiples method: ~$2.0M TTM revenue (small and recently declining) with a conservative 3.0x EV/Revenue multiple (vs 5-8x for larger, higher-margin diagnostics peers like Guardant Health/Exact Sciences, discounted heavily for AIDX's sub-scale, ~18-30% gross margins, and heavy cash burn) = ~$6.1M EV; added back ~$4.2M cash net of minimal debt = ~$10.3M equity value; divided by an estimated ~12.0M shares outstanding (adjusted upward for likely subsequent dilution).

Reasoning: Newly public (IPO Feb 2026, now down sharply from its $50 IPO price) pre-profitability multi-cancer early-detection diagnostics lab with small, volatile, recently-declining revenue and cash burn exceeding revenue, so a DCF is not reliable; a heavily-discounted revenue multiple vs larger diagnostics peers, adjusted for net cash, is the most defensible approach for real but early-stage/high-risk financials.